Your browser doesn't support javascript.
loading
Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress.
Knowles, Juliet K; Helbig, Ingo; Metcalf, Cameron S; Lubbers, Laura S; Isom, Lori L; Demarest, Scott; Goldberg, Ethan M; George, Alfred L; Lerche, Holger; Weckhuysen, Sarah; Whittemore, Vicky; Berkovic, Samuel F; Lowenstein, Daniel H.
Afiliación
  • Knowles JK; Department of Neurology, Division of Child Neurology, Stanford University School of Medicine, Stanford, California, USA.
  • Helbig I; Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Metcalf CS; Epilepsy NeuroGenetics Initiative, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Lubbers LS; Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Isom LL; Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Demarest S; Institute of Clinical Molecular Biology, University of Kiel, Kiel, Germany.
  • Goldberg EM; Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • George AL; Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
  • Lerche H; Citizens United for Research in Epilepsy, Chicago, Illinois, USA.
  • Weckhuysen S; Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Whittemore V; Department of Pediatrics and Neurology, University of Colorado, School of Medicine, Aurora, Colorado, USA.
  • Berkovic SF; Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Lowenstein DH; Epilepsy NeuroGenetics Initiative, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Epilepsia ; 63(10): 2461-2475, 2022 10.
Article en En | MEDLINE | ID: mdl-35716052
ABSTRACT
The genetic basis of many epilepsies is increasingly understood, giving rise to the possibility of precision treatments tailored to specific genetic etiologies. Despite this, current medical therapy for most epilepsies remains imprecise, aimed primarily at empirical seizure reduction rather than targeting specific disease processes. Intellectual and technological leaps in diagnosis over the past 10 years have not yet translated to routine changes in clinical practice. However, the epilepsy community is poised to make impressive gains in precision therapy, with continued innovation in gene discovery, diagnostic ability, and bioinformatics; increased access to genetic testing and counseling; fuller understanding of natural histories; agility and rigor in preclinical research, including strategic use of emerging model systems; and engagement of an evolving group of stakeholders (including patient advocates, governmental resources, and clinicians and scientists in academia and industry). In each of these areas, we highlight notable examples of recent progress, new or persistent challenges, and future directions. The future of precision medicine for genetic epilepsy looks bright if key opportunities on the horizon can be pursued with strategic and coordinated effort.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Epilepsia / Medicina de Precisión Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Epilepsia Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Epilepsia / Medicina de Precisión Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Epilepsia Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos